Paracoccus denitrificans

Identity: Taxonomy, Nomenclature, and Natural Sources

Paracoccus denitrificans is a Gram-negative bacterium of significant biochemical and biotechnological interest. It is a metabolically versatile alphaproteobacterium first isolated in 1910 by Martinus Beijerinck. Formerly known as Micrococcus denitrificans, the bacterium was reclassified in 1969 to Paracoccus denitrificans by D. H. Davis. Taxonomically, it belongs to the domain Bacteria, phylum Proteobacteria (Pseudomonodota), class alpha subdivision, family Paracoccaceae.

It is a Gram-negative facultative anaerobe with non-motile coccoid cells typically around 1 µm in diameter, with an optimal growth temperature in the range of 30–36 °C. It is typically rod-shaped but assumes spherical shapes during the stationary phase, and, like all Gram-negative bacteria, it has a double membrane with a cell wall. The genome of P. denitrificans was sequenced in 2004.

Metabolically, Paracoccus denitrificans is very flexible and has been recorded in soil in both aerobic and anaerobic environments. The microbe has the ability to live in many different kinds of media and environments and is known to be an extremophile. It can obtain energy both from organic compounds, such as methanol and methylamine, and from inorganic compounds, such as hydrogen and sulfur. The first strain of Paracoccus denitrificans was isolated from soil more than one century ago by Beijerinck and Minkman.

Natural Habitat

It is a Gram-negative bacterium recognized for its metabolic versatility, including its capacity for denitrification and energy production via various pathways. Strains of Paracoccus denitrificans have been isolated from activated sludge that degrade a variety of methylated amines under both aerobic and anaerobic conditions; another strain is chemolithoautotrophically capable of degrading quaternary carbon compounds such as dimethylmalonate under denitrifying conditions. The organism is principally a soil microorganism but is widely distributed across diverse environments where nitrogen cycling occurs.

Common Forms and Preparations

In the context of nutritional supplementation, P. denitrificans is not consumed directly as an intact living bacterium. Its primary relevance to the supplement industry is as a microbial production platform — specifically, as a fermentation host used to biosynthesize Coenzyme Q10 (ubiquinone-10, CoQ10), which is then extracted, purified, and incorporated into finished supplement products. CoQ10 is currently produced on an industrial scale through fermentation by natural or mutant microorganisms such as Agrobacterium tumefaciens, Paracoccus denitrificans, Rhodobacter sphaeroides, or by recombinant Escherichia coli. It is commercially produced by fermentation process, hence constructing the high yielding CoQ10 producing strains is a prerequisite for cost-effective production.

The organism has also appeared in some commercial nutritional preparations as a whole-cell lysate or biomass fraction, and certain supplement blends list it as a constituent ingredient alongside other probiotic bacteria. In modern herbal combinations, Paracoccus denitrificans is sometimes included alongside other probiotic strains and plant-based extracts to create synergistic effects, with such combinations formulated to enhance immune function, promote detoxification, and support overall vitality. However, this application lacks a rigorous peer-reviewed clinical evidence base, as discussed in subsequent sections.

Historical and Traditional Use

The use of Paracoccus denitrificans in direct medicinal remedies is not well documented, as much of its early study focused on its environmental significance. Unlike plant-derived botanicals with centuries of documented ethnobotanical use, P. denitrificans is a microorganism discovered in the context of modern microbiology. Its original isolation in 1910 by Beijerinck was motivated by interest in soil nitrogen cycling, not therapeutic application. The organism therefore has no traditional medicinal use in any culture or time period that can be verified in the peer-reviewed literature.

The modern interest in P. denitrificans as a supplement-relevant organism emerges entirely from 20th- and 21st-century biotechnology, specifically from the discovery that it is a high-yielding natural producer of CoQ10, a compound with widely studied nutraceutical properties. Paracoccus denitrificans, Agrobacterium tumefaciens, and Rhodobacter sphaeroides are the naturally high producers of CoQ10. CoQ10, an important antioxidant molecule playing a major role in the electron transport chain, has been commercially produced by fermentation process for use in oral nutraceutical formulations.

Key Constituents and Active Compounds

Coenzyme Q10 (Ubiquinone-10)

The most commercially and scientifically significant compound produced by P. denitrificans is Coenzyme Q10 (CoQ10), also known as ubiquinone-10. CoQ10, also referred to as ubiquinone-10, is a lipid-soluble quinone that serves as an electron carrier in the electron transport chain of aerobic respiration and is widely distributed among organisms. Complex I (NADH:ubiquinone oxidoreductase) is a large, multisubunit, membrane-bound enzyme that couples the oxidation of NADH and reduction of ubiquinone to the translocation of four protons across the inner mitochondrial membrane, contributing to the proton motive force that is used to power ATP synthesis.

Ubiquinone-10 (CoQ10) is a vitamin-like lipophilic component of the membrane-bound electron transport system with a wide range of therapeutic, nutraceutical, and cosmeceutical applications. It is an important molecule involved in cellular energy production and is also known for its antioxidant role, as it protects the body against oxidative stress. However, the synthesis of CoQ10 in the body declines with age, resulting in the need for external supplementation.

The CoQ10 Biosynthetic Pathway in P. denitrificans

To provide the first CoQ10 precursor decaprenyl diphosphate (DPP) from farnesyl diphosphate, the DPP synthase gene ddsA from Paracoccus denitrificans has been a key subject of study. Improved supply of the second CoQ10 precursor, para-hydroxybenzoate (pHBA), has been obtained through metabolic engineering of the shikimate pathway. Prenylation of pHBA with DPP and subsequent decarboxylation, hydroxylation, and methylation reactions yield CoQ10.

DXP synthase, encoded by the dxs gene, initiates the non-mevalonate pathway, significantly influencing coenzyme Q10 production by providing critical precursors. The non-mevalonate pathway, utilized by CoQ10-producing bacteria, synthesizes key precursors like IPP, which is essential for CoQ10 biosynthesis.

Notably, P. denitrificans and related strains produce only one class of quinone — CoQ — in contrast to E. coli, which produces various classes of quinones (CoQ, MK, and DMK). These natural producer strains produce CoQ10 in the range of 30–130 mg/L. Microbial fermentation using yeasts or bacteria offers several advantages over chemical and semi-chemical synthesis, including specificity towards the all-trans biologically active isomer of CoQ10 and the reduced production of environmentally hazardous waste.

P. denitrificans uses ubiquinone-10 as its sole quinone in the cell, the same as used by the human respiratory chain and in many mammalian species. This biochemical alignment with human cellular chemistry is one of the reasons the organism has attracted interest as both a production platform and a scientific model.

Other Biochemically Notable Compounds and Features

Beyond CoQ10, P. denitrificans possesses a full complement of respiratory chain complexes, including Complex I (NADH:ubiquinone oxidoreductase), cytochrome bc1 (Complex III), and cytochrome c oxidase (Complex IV), all of which are closely homologous to their mitochondrial counterparts. Early research indicated that Paracoccus denitrificans especially resembled mitochondria. The bacterium encloses within itself the biochemistry of the mitochondrial respiratory chain and oxidative phosphorylation. While these features are found randomly distributed in other species of aerobic bacteria, to date all of these are only found together in Paracoccus denitrificans.

The organism also carries enzymes of biotin metabolism. Biotin (vitamin H), a sulfur-containing fatty acid derivative, functions as the covalently bound enzyme cofactor required by three domains of life. The representative biotin-requiring enzyme refers to the AccB subunit of acetyl-CoA carboxylase (ACC), catalyzing the first committed step of fatty acid biosynthesis. P. denitrificans possesses regulatory genes (BioR homologs) that govern the metabolism of this cofactor, as established in peer-reviewed research.

Mechanisms of Action

Oxidative Phosphorylation and Mitochondrial Mimicry

Similarities between the aerobic respiratory chain and membrane composition of P. denitrificans and those of eukaryotic mitochondria have stimulated the use of P. denitrificans as a model for oxidative phosphorylation. Respiratory complex I (NADH:ubiquinone oxidoreductase) is a crucial metabolic enzyme that couples the free energy released from NADH oxidation and ubiquinone reduction to the translocation of four protons across an energy-transducing membrane, contributing to the proton motive force used to synthesise ATP.

By confirming the four-proton stoichiometry for mammalian complex I and demonstrating the same value for a bacterial complex, researchers have established the utility of P. denitrificans complex I as a model system for the mammalian enzyme. P. denitrificans is the first system described in which mutagenesis in any complex I core subunit may be combined with quantitative proton-pumping measurements for mechanistic studies.

A feasible mechanism for the evolution of a eukaryotic mitochondrion, from the plasma membrane of an ancestral aerobic bacterium resembling P. denitrificans to the inner mitochondrial membrane, has been suggested. This endosymbiotic theory context is scientifically significant: it implies that CoQ10 produced by P. denitrificans fermentation is structurally and functionally equivalent to CoQ10 found in human mitochondria.

Denitrification Pathway

Fermentative metabolism is absent in P. denitrificans; energy conservation under anaerobic growth conditions is by denitrification — the reduction of nitrate and nitrite to nitric oxide, nitrous oxide, and dinitrogen — reactions that are coupled to the generation of proton motive force (PMF). Some strains are capable of "aerobic denitrification," the complete dissimilation of nitrate to dinitrogen or nitrous oxide under aerobic growth conditions. The microbe can also oxidize ammonia to nitrite while grown on organic energy sources, a process known as "heterotrophic nitrification."

One-Carbon Metabolism

One-carbon growth substrates are oxidized to carbon dioxide, which is then fixed into biomass by the Calvin–Benson cycle. P. denitrificans is the prototypical "autotrophic methylotroph," and was among the first methylotrophs from which genes involved in C1 metabolism were cloned and characterized.

Scientific Evidence by Area of Use

1. CoQ10 Production Platform: Industrial and Fermentation Evidence

The strongest area of established scientific evidence concerns the use of P. denitrificans as a microbial factory for CoQ10. This is well-supported at the biotechnological level by numerous peer-reviewed fermentation studies.

Paracoccus denitrificans ATCC 19367, a biochemically versatile organism, was selected to carry out studies on CoQ10 yield improvement. The wild-type strain was subjected to iterative rounds of mutagenesis using gamma rays and NTG, followed by selection on various inhibitors like CoQ10 structural analogues and antibiotics.

A superior mutant strain P-87 generated from Paracoccus denitrificans ATCC 19367 showed 1.25-fold improvement in specific CoQ10 content higher than the wild-type strain at shake flask level. Other researchers developed induced mutant PF-P1, which showed 1.73-fold (1.51 mg/g) enhancement in the specific CoQ10 content compared to the wild-type strain. They further developed a process technology for CoQ10 production at 2L bioreactor level and achieved 2.44 mg/g specific CoQ10 yield.

In submerged batch fermentation, the yield of CoQ10 was 12.22 mg/L when 40 g/L glycerol was used, with specific growth rate (0.056/h) and growth associated constant (α=0.680 mg/g) higher as compared to other concentrations.

At 30% dissolved oxygen (of air saturation), the highest titre of 75.49 mg/L was observed at 96 h with 38 g/L of dry cell weight.

A minimum of 500 mg/L yield is expected from a commercially viable strain, which implies that these natural strains have failed to meet the industrial requirement for production of CoQ10. Ongoing research aims to address this limitation through metabolic engineering and process optimization. Evidence strength: Robust at the level of microbial biochemistry and fermentation science; no clinical trials exist using P. denitrificans itself as the supplement agent.

2. Coenzyme Q10 (the End-Product): Clinical Evidence

It is critical to distinguish between the clinical evidence for CoQ10 as a nutraceutical — which is extensive — and the evidence directly attributable to P. denitrificans as a direct supplement ingredient. P. denitrificans is a production organism; the bioactive compound is CoQ10 itself, extracted and purified before consumer use. CoQ10 is a blockbuster nutraceutical molecule often used as an oral supplement in the supportive therapy for cardiovascular diseases, cancer, and neurodegenerative diseases.

CoQ10 has been widely used as a dietary supplement, as well as for nutraceuticals, immune booster, and in cosmetics. It is also widely employed for therapeutic applications such as heart disease, Alzheimer's and Parkinson's diseases, and breast cancer. It is an important molecule involved in cellular energy production and is also known for its antioxidant role, as it protects the body against oxidative stress.

The clinical evidence for CoQ10 spans multiple therapeutic areas. However, no published clinical trials have specifically compared P. denitrificans-derived CoQ10 against CoQ10 from other production sources (e.g., Rhodobacter sphaeroides or yeast) in terms of clinical outcomes. The fermentation source is considered a manufacturing distinction, not a therapeutic distinction, once the molecule is purified.

3. Respiratory Chain / Mitochondrial Function Research

The organism has been used extensively as a model for studies of denitrification, cytochrome c biogenesis, lithotrophy using thiosulphate as a source of energy, methylotrophy, and carbon metabolism more broadly. Due to its essential role in metabolism and energy production, mutations in complex I and its associated proteins are the origin of a wide range of neuromuscular and metabolic disorders. This has made P. denitrificans valuable as a model for understanding conditions including mitochondrial myopathy, Leigh syndrome, and related energy-metabolism disorders — but this is entirely basic science research, not a clinical application of P. denitrificans supplementation.

Evidence strength: Strong at the level of mechanistic biochemistry and cell biology; no direct human clinical trials on the organism as a supplement.

4. Potential Probiotic and Gut Health Effects

In recent years, the use of P. denitrificans in nutritional and medicinal products has gained attention due to its probiotic potential and positive effects on gut health. While it is more commonly recognized in scientific literature for its ecological and biotechnological roles, interest in its possible probiotic effects has grown.

However, it must be stated clearly that as of the current literature search, no peer-reviewed clinical trials or robust human studies have established safety or efficacy of P. denitrificans as a probiotic supplement in humans. The claims of probiotic benefit derive from marketing assertions and are not validated in the clinical literature. Evidence strength: Currently absent at the human clinical trial level for direct supplementation.

5. Hypergravity Tolerance and Astrobiology

While not a health-relevant application, the bacterium's remarkable physical resilience has been studied scientifically. Recent research carried out on extremophiles in Japan involved a variety of bacteria including Paracoccus denitrificans being subject to conditions of extreme gravity. The bacteria were cultivated while being rotated in an ultracentrifuge at high speeds corresponding to 403,627 times g. Paracoccus denitrificans displayed not only survival but also robust cellular growth under these conditions of hyper-acceleration, which are usually found only in cosmic environments. Analysis showed that the small size of prokaryotic cells is essential for successful growth under hypergravity. The research has implications for the feasibility of the existence of exobacteria and panspermia.

Body Systems and Health Areas of Association

The body systems associated with P. denitrificans — primarily through its role as a CoQ10 production organism and as a model for mitochondrial biology — include the following:

• Cardiovascular system: CoQ10 produced via P. denitrificans fermentation is used in formulations targeting heart function and mitochondrial energy support. CoQ10 is often used as an oral supplement in the supportive therapy for cardiovascular diseases.
• Neurological system: CoQ10 is also widely employed for therapeutic applications such as Alzheimer's and Parkinson's diseases.
• Cellular energy production / mitochondrial function: Complex I is a key site for cellular reactive oxygen species generation, particularly during ischemia reperfusion injury. Mutations in complex I and its associated proteins are the origin of a wide range of neuromuscular and metabolic disorders.
• Antioxidant defense: CoQ10 is known for its antioxidant role, as it protects the body against oxidative stress.
• Hepatic / autoimmune system (safety-relevant association): A linear conformational mimicry between microbial proteins and human mitochondrial antigens has been demonstrated for several bacteria including Paracoccus denitrificans, in the context of primary biliary cholangitis (PBC).
• Gut microbiome (proposed, not established): Some supplement preparations position the bacterium in the context of gut health, though clinical evidence for this application is absent.

Dosage Forms and Reported Dosages

P. denitrificans itself, as a whole organism or biomass-derived ingredient, does not have established human dosage guidelines in any peer-reviewed clinical study, pharmacopoeia monograph, or regulatory guidance document (e.g., NIH ODS, EFSA, EMA) identified in this literature review. No randomized controlled trials specifying doses of P. denitrificans as a direct supplement were located.

For the end-product CoQ10 produced by P. denitrificans fermentation:

• In submerged batch fermentation studies, CoQ10 yields of 12.22 mg/L were achieved using 40 g/L glycerol as a carbon source. These are production yields, not human dosage figures.
• In optimized fed-batch fermentation with the PF-P1 fusant strain, titres of 75.49 mg/L were observed at 96 hours.
• Dosages of extracted CoQ10 in published human clinical trials (unrelated to the specific bacterial production source) have ranged from approximately 100 mg to 1,200 mg per day, but these dosages attach to the purified CoQ10 molecule, not to any P. denitrificans-specific preparation.

Any supplement product label listing P. denitrificans itself as a dose-specified probiotic ingredient must be evaluated against the absence of any dose-finding or dose-ranging clinical studies in the peer-reviewed literature as of the current search date.

Safety Considerations and Interactions

Pathogenicity Status

Paracoccus denitrificans is not a known human pathogen. This is the most fundamental safety-relevant finding regarding the organism. Its historical use in research settings and industrial fermentation has not been associated with infectious disease in healthy adults.

ATCC Biosafety Classification

Certain strains of P. denitrificans archived at the American Type Culture Collection (ATCC) are classified as biosafety level 3 products. These products are intended for laboratory research use only and are explicitly not intended for human or animal therapeutic use or consumption. It must be noted that the biosafety level assignment by ATCC for a research-grade culture does not necessarily equate to consumer safety risk, but underscores that the organism has not been evaluated or approved for direct human supplementation by regulatory agencies.

Molecular Mimicry and Autoimmune Associations

An important and scientifically documented safety concern relates to the structural similarity between proteins of P. denitrificans and human mitochondrial antigens. A linear conformational mimicry between microbial proteins and human mitochondrial antigens has been demonstrated for Paracoccus denitrificans in the context of primary biliary cholangitis (PBC). Sayers and Baum (1976) raised the question of possible cross-reactivity of human antimitochondrial antibodies with membrane vesicles of Paracoccus denitrificans.

Environmental triggers including bacteria can induce autoimmune reactions in genetically susceptible patients, evident by the presence of humoral and cellular responses to intracytoplasmic antigens including the anti-mitochondrial antibody. Bacteria containing lipoylated proteins can lead to immune responses targeting their lipoylated proteins via molecular mimicry.

Antimitochondrial antibodies (AMA) are the hallmark serological feature present in over 90% of individuals diagnosed with PBC. In PBC, AMA are autoantibodies that target antigens, including pyruvate dehydrogenase complex (PDC), 2-oxoglutarate dehydrogenase complex (OGDC), and branched-chain oxo-acid dehydrogenase complex (BCOADC), all located on the inner mitochondrial membrane.

The theoretical implication is that individuals with PBC or with a genetic predisposition to autoimmune liver disease could potentially have an exaggerated response to P. denitrificans proteins, due to the structural resemblance between bacterial membrane components and inner mitochondrial membrane antigens. This concern is derived from structural immunology data and is not yet tested in clinical studies of P. denitrificans supplementation.

Gram-Negative Bacterial Cell Wall Components

As a Gram-negative bacterium, P. denitrificans contains lipopolysaccharide (LPS) in its outer membrane. LPS is a potent inflammatory molecule and endotoxin, which can trigger inflammatory and immune responses if introduced into the systemic circulation. Any whole-cell preparation of P. denitrificans for oral use would need to account for LPS content and its effects, particularly in individuals with increased intestinal permeability. No published clinical data address this question directly in the context of this organism as a supplement.

Absence of Regulatory Approval for Direct Supplementation

No entry for Paracoccus denitrificans as a direct dietary supplement ingredient appears in the NIH Office of Dietary Supplements fact sheets, the EFSA Register of Questions, the WHO monographs on medicinal plants, or the European Pharmacopoeia. The organism's relevance to the supplement sector is defined by its role as a CoQ10 production platform; the fermentation-derived CoQ10 itself is the regulated nutraceutical ingredient, not the bacterium.

Drug and Supplement Interactions

No peer-reviewed human pharmacokinetic or pharmacodynamic interaction studies exist for P. denitrificans whole-cell preparations or biomass with pharmaceutical agents. Interaction concerns that apply to CoQ10 itself (e.g., with warfarin or statins) are properties of the purified CoQ10 molecule and are not attributable to the bacterial production organism.

Scientific Model Organism Status

Similarities between the aerobic respiratory chain and membrane composition of P. denitrificans and those of eukaryotic mitochondria have stimulated its use as a model for oxidative phosphorylation. The organism has also been used extensively as a model for studies of denitrification, cytochrome c biogenesis, lithotrophy, methylotrophy, and carbon metabolism more broadly. Through the application of structural biology and modern genome-based approaches, work on P. denitrificans continues to make significant contributions across multiple areas of microbiology.

The announcement of genomic sequences for P. denitrificans greatly facilitated the development of it as a model organism for extensive investigations of molecular mechanisms (endosymbiotic theory) implicated in denitrification and as a possible ancestor for the eukaryotic mitochondrion.

Researchers have developed the α-proteobacterium Paracoccus denitrificans as a suitable bacterial model system for mitochondrial complex I. In its most minimal form, as typically found in α-proteobacteria, complex I is composed of 14 conserved catalytic "core" subunits; the seven core subunits of the hydrophilic domain catalyze electron transfer from NADH to ubiquinone, and the seven core subunits in the membrane domain contain the proton pumps.

The ability to metabolize compounds of hydrogen and sulfur, such as thiosulfate, has led to the microbe being exploited as a model organism for the study of poorly characterized sulfur compound transformations.

Summary of Evidence Strength

• CoQ10 production via fermentation: Well-established, peer-reviewed evidence. Multiple studies demonstrate P. denitrificans as an effective natural producer with yields being progressively improved through mutagenesis and process optimization.
• Mitochondrial/respiratory chain model: Strong mechanistic evidence. Widely used in basic science; contributions include defining Complex I proton-pumping stoichiometry and enabling mutagenesis studies of all core subunits.
• Direct supplementation in humans: No clinical evidence exists. No human trials, dose-ranging studies, or efficacy studies for P. denitrificans as a probiotic or direct oral supplement have been identified in the peer-reviewed literature.
• Molecular mimicry / PBC association: Preliminary, mechanistic-level evidence from structural immunology; no prospective clinical studies confirm a causal role or a risk for supplement users.
• Probiotic benefit claims: Unsubstantiated by peer-reviewed human data; these claims, found on supplement and marketing websites, are not supported by trials in humans.

References

• Spiro S, Richardson DJ. Microbe Profile: Paracoccus denitrificans — a versatile model. Microbiology. 2026. PMC12848317.
• Tokdar P, et al. Molecular, Physiological and Phenotypic Characterization of Paracoccus denitrificans ATCC 19367 Mutant Strain P-87 Producing Improved Coenzyme Q10. PMC. 2015. PMC4363252.
• Tokdar P, et al. Molecular, Physiological and Phenotypic Characterization of Paracoccus denitrificans ATCC 19367 Mutant Strain P-87 Producing Improved Coenzyme Q10. PubMed. 2015.
• Paracoccus denitrificans — Wikipedia.
• Feng Y, et al. Paracoccus denitrificans possesses two BioR homologs having a role in regulation of biotin metabolism. MicrobiologyOpen. 2015. PMC4554459.
• Nag A, et al. CoQ10 a super-vitamin: review on application and biosynthesis. PMC5943198.
• Henke NA, et al. Coenzyme Q10 Biosynthesis Established in the Non-Ubiquinone Containing Corynebacterium glutamicum by Metabolic Engineering. Front. Bioeng. Biotechnol. 2021. PMC8042324.
• Rydström Lundin C, et al. Paracoccus denitrificans: a genetically tractable model system for studying respiratory complex I. Scientific Reports. 2021. PMC8115037.
• Melo AMP, et al. Respiratory Complex I in Bos taurus and Paracoccus denitrificans Pumps Four Protons across the Membrane for Every NADH Oxidized. PMC5377811.
• Deguchi S, et al. Microbial growth at hyperaccelerations up to 403,627 × g. Proc Natl Acad Sci USA. 2011.
• Mendoza-Hoffmann F, et al. Inhibitory to non-inhibitory evolution of the ζ subunit of the F1FO-ATPase of Paracoccus denitrificans. Front. Mol. Biosci. 2023.
• Gray MW. Mitochondrial Evolution. Cold Spring Harb Perspect Biol. 2012. PMC3428767.
• Enhanced production and characterization of coenzyme Q10 from Rhodobacter sphaeroides using a potential fermentation strategy. ScienceDirect. 2022.
• Fermentation kinetics of production of ubiquinone-10 by Paracoccus dinitrificans NRRL B-3785. Food Sci. Biotechnol. Springer. 2011.
• Unravelling Coenzyme Q10 pathway could pave way to industrial production. The Microbiologist. 2023.
• Paracoccus denitrificans — Knowledge and References. Taylor & Francis.
• Primary Biliary Cholangitis — StatPearls. NCBI Bookshelf. NBK459209.
• Primary Biliary Cholangitis Etiology. Rare Disease Advisor. 2024.
• Anti-mitochondrial autoantibodies — milestone or byway to primary biliary cholangitis? PMC5326641.
• Paracoccus denitrificans ATCC 19367. American Type Culture Collection (ATCC).
• An improved medium for the anaerobic growth of Paracoccus denitrificans Pd1222. PMC3907716.
• Tokdar P, Ranadive P, Deshmukh SK, Khora SS. Optimization of Fermentation Process Conditions for the Production of CoQ10 using Paracoccus denitrificans ATCC 19367 Fusant Strain PF-P1. IJERT. 2017.
• Autoantibodies in Primary Biliary Cholangitis: From Classical Markers to Emerging Targets. J Clin Med. 2025.
• Metabolic engineering of Paracoccus denitrificans for dual degradation of sulfamethoxazole and ammonia nitrogen. Microbiology Spectrum. 2023.